Format

Send to:

Choose Destination
See comment in PubMed Commons below
Immunology. 2011 Jun;133(2):197-205. doi: 10.1111/j.1365-2567.2011.03427.x. Epub 2011 Mar 25.

Studies on the antigenicity of the NKG2D ligand H60a in tumour cells.

Author information

  • 1Department of Pathology, University of California-San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0612, USA.

Abstract

H60a is a minor histocompatibility antigen expressed in BALB and 129/Sv but not C57BL/6 mouse strains. The majority of CD8+ T cells in C57BL/6 mice responding to BALB.B splenocytes are specific for H60a. Interestingly, H60a is expressed constitutively on tumour cells, but its nature as a tumour rejection antigen, as a parallel to its function as a transplant rejection antigen, has not been studied. In this report, we show that tumour cells that constitutively express H60a at the cell surface can be recognized by H60a-specific T cells. Furthermore, when H60a-expressing sarcoma cell lines are transplanted into C57BL/6 mice, H60a-specific T cells can be found at high percentages among the tumour-infiltrating CD8+ T cells. These findings were seen in C57BL/6 but not F1 (C57BL/6×129) mice (which express H60a), suggesting that endogenous tolerance mechanisms suppress the antigenic properties of H60a. Our findings have implications for the generation of tumour vaccines against human natural killer group 2D ligands, such as MHC class I chain-like gene A, that are also transplantation antigens.

© 2011 The Authors. Immunology © 2011 Blackwell Publishing Ltd.

PMID:
21438873
[PubMed - indexed for MEDLINE]
PMCID:
PMC3088982
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Blackwell Publishing Icon for PubMed Central
    Loading ...
    Write to the Help Desk